Oral Lichen Planus Clinical Trial
Official title:
Comparative Efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine With Triamcinolone in Orabase as Symptomatic Treatment of Oral Lichen Planus, A Randomized Controlled Trial
Background: Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous autoimmune
disease mainly affecting stratum basal of the epithelium. It is very painful and hamper the
daily routine of patients e.g. (talking, drinking, eating, maintaining normal relationships).
Different topical treatments have been tried for the symptomatic relief of OLP which include
topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs) retinoids,
photochemotherapy; amitryptaline; thalidomide; amlexanox and traditional medicines such as
curcumin, selenium-ACE combined with itraconazole, glycyrrhiza glabra and aloe vera. But the
exact treatment is still unknown.
Objective: To compare the efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine
cocktail with Triamcinolone as topical treatment of OLP Subjects and Methods: 40 patients of
symptomatic OLP will be randomly divided in to study and control group. Study group will be
given a cocktail containing dexamethasone, doxycycline, nystatin and promethazine and will be
advised to rinse with 1 and half teaspoon of this cocktail 3 times a day for 2 minutes for
the period of 8 weeks. Study group is also advised to apply an orabase containing 0.1%
triamcinolone on lesions 3 times a day for the period of 8 weeks. The control group will be
advised to apply only triamcinolone orabase 3 times a day for 8 weeks.
Introduction Oral lichen planus (OLP) is a chronic inflammatory mucocutaneous autoimmune
disease mainly affecting stratum basal of the epithelium. It is T-cell mediated immunological
disease that mostly occurs bilaterally on buccal mucosa while tongue and gingiva are other
commonly involved sites while palatal mucosa and floor of the mouth are rarely affected
(Roopashree MR, 2010, Torrente-Castells et al., 2010, Alves et al, 2010). The prevalence of
OLP in general population is 0.1-4% (Sugerman et al., 2002) mainly affecting the middle-aged
and elderly people (Ingafou et al., 2006) and female: male ratio 2:1 (Shen et al., 2012).
It has six clinical forms: keratotic, reticular, papular, plaquelike white patches, erosive,
atrophic, and bullous (Shen et al., 2012). Reticular and erosive form are most common (Alves
et al, 2010). Keratotic reticular, papular, plaque like white patches often present with no
complaints (Oczko et al, 2011), while erosive, atrophic, and ulcerative lesions are a painful
or present with a burning sensation, and thus make eating, speaking, and swallowing difficult
(Thongprasom et al., 2007). Histologically, a subepithelial infiltration in the form of dense
band of lymphocytes, increased numbers of intraepithelial lymphocytes and the liquefaction
degeneration of basal keratinocytes is seen in OLP (Payeras et al., 2013).
Several predisposing factors have been identified which may cause or progress OLP which
include immunity, infection, genetics, stress and endocrine. Recent researches showed an
increased activity of prolidase and oxidative stress in OLP patients, causing disturbance in
the antioxidant defense system (Batu et al, 2016, Ergun et al, 2011). Although the exact
cause is still not clear, facts show that an immunological process is involved in OLP which
is activated by an unknown antigen that change the basal keratinocytes of the oral mucosa and
these alterations cause the cell immune response to attack the keratinocytes. (Ismail et al.,
2007, Payeras et al., 2013). This antigen may be intrinsic or extrinsic, or both. Evidence
shows that bacteria can be one of the etiologic factors of OLP. An association has already
been found between OLP and infection, such as Ebstein Barr virus, Hepatitis C virus,
Helicobacter pylori and Candida Albicans. A study also pointed out the allergy to various
antigens coming in direct contact with oral cavity to contribute to the etiology of OLP. (D.
Wray, 2000) As the etiology is not known therefore there is no definitive treatment for OLP
and the mainstay of therapy for improving the life of these patients is symptomatic topical
treatment. Topical treatments which have been tried for the symptomatic OLP include topical
corticosteroids (TCSs), including betamethasone, clobetasol, dexamethasone and triamcinolone;
topical calcineurin inhibitors (TCIs) such as pimecrolimus, tacrolimus or ciclosporin;
retinoids such as tretinoin; photochemotherapy; amitryptaline; thalidomide; amlexanox and
traditional medicines such as curcumin, selenium-ACE combined with itraconazole, glycyrrhiza
glabra and aloe vera.
In a study both tacrolimus 0.1% ointment and pimecrolimus 1% cream were found equally
effective for the treatment of OLP (Vohra et al., 2016). Similarly another study showed that
Clobetasol propionate (0.05%) was found more effective than triamcinolone acetonate (0.1%)
and tacrolimus orabase (0.03%) for the management of OLP. This study also found that
triamcinolone 0.1% is superior to tacrolimus 0.03% in terms of effectiveness for the
treatment of OLP.(Sivaraman et al., 2016) According to another study both triamcinolone and
curcumin paste were found almost equally effective in reducing the pain and improving the
appearance of OLP lesions (Kia et al., 2015). In another study it was concluded that
combination of Selenium-ACE, corticosteroid and antifungal is a better treatment regimen for
the treatment of erosive ulcerative OLP than a capsule of 100 mg Itraconazole plus
dexamethsone mouthwash or dexamethasone alone (Belal, 2015). In another similar study
cocktail of clobetasol, ketoconazole and amitryptiline was found more efficacious than
diluted dexamethasone, nystatin and Diphenhydramine elixir (Javadzadeh et al, 2008). In a
comparative study tacrolimus 0.1% cream was found more effective than 0.05% clobetasol
propionate cream in reducing pain and healing of OLP lesions (Hettiarachchi et al., 2016).
Both thalidomide and dexamethasone were found almost equally effective in another trail (Wu
et al., 2010). In a trail of comperison between amlexanox paste and dexamethasone paste both
were found equally effective at the end of 7 days in terms of reduction in clinical signs
(erosion) and symptoms like pain and burning sensation (Fu et al., 2012). Some herbal
medicines have also been tried like Glycyrrhiza glabra and Aloe vera, in a trail to compare
the efficacy of 1% Glycyrrhiza glabra In orabase with 0.1% Triamcinolone Acetonide both were
found almost equally effective in reducing the pain and improving the appearance of OLP
lesions (Najafi et al., 2016) and in another trail both Aloe Vera Mouthwash and Triamcinolone
Acetonide were found almost equally effective in reducing the pain and in reducing the size
of OLP lesions (Mansourian et al., 2011) So steroids remained the mainstay of treatment for
OLP but evidence points towards the involvement of bacterial and fungal infections in the
pathogenesis of OLP as according to a recent study disbiosis was found in the buccal surface
mucosa of patients of OLP, as certain bacterial species were found in greater no in buccal
mucosa of OLP patients so they concluded that an association exists between bacterial
disbiosis of buccal mucosa and OLP (He et al., 2017). Similar studies showed that antibiotics
relieved symptoms of OLP effectively (Backman & Jontell, 2007; Carbone et al, 1999). OLP is a
disease which reduces the individual's resistance and changes the candida albican's role from
commensalism to parasitism which is among the normal flora of oral cavity or candida may
secondarily infect the OLP lesions and exacerbate the signs and symptoms (santosh gowdru
shivanandappa, 2012). In a study 62% of OLP patients were found allergic to different
allergens which come in contact with mucosa in daily life so they found that association
exists between OLP and allergy (D. Wray, 2000). According to another study mast cell
hyperplasia was seen in OLP patients which suggests their role in pathogenesis of OLP (Ankle
R et al, 2007) The most used therapy is TCSs however its effectiveness is limited due to
opportunistic oral infections in patients with OLP. Adjunct antibiotic therapies have been
used to aid in symptomatic relief and improved response has been observed as compared to TCSs
alone. however none of the combined therapies have used antifungal as an additive in their
local applications, as candida is one of the opportunistic organisms that colonizes affected
sites. Role of allergy mechanisms have also been discussed.
Rationale Evidence of involvement of bacterial and fungal infections and allergy in the
pathogenesis of OLP suggests the need for the use of antibiotic, anti fungal and
antihistamine for the topical treatment of OLP and there is a gap in literature. That's why
current trail is being done to evaluate the efficacy of topical doxycycline, nyastatin and
promethazine along with dexamethasone for the symptomatic relief of OLP.
Hypothesis Dexamethasone, Doxycycline, Nystatin and Promethazine combination topical rinse
are more effective for the treatment of OLP than Triamcinolone alone Objective To compare the
efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine combination topical rinse
with Triamcinolone rinse as topical treatment of Oral Lichen Planus.
Operational Definitions • Oral Lichen Planus: Oral lichen planus (OLP) is a chronic
inflammatory mucocutaneous autoimmune disease mainly affecting stratum basal of the
epithelium.
Subjects and Methods Study Type Randomized control trail (Parallel arm study). Study Setting
Department of Oral Medicine & Diagnosis and Department of Dermatology. Madina Teaching
Hospital Faisalabad.
Duration The study will be completed in 3 months after the approval of synopsis. Study
Population Patients of oral lichen planus visiting Department of Oral Medicine & Diagnosis
and Department of Dermatology. Madina Teaching Hospital Faisalabad.
Sampling Technique Purposive Sampling, (Inclusion/exclusion criteria based)
Sample Selection Inclusion Criteria
1. Histopathologically proven patients of OLP of all age groups complaining of symptoms
such as pain, burning sensitivity to hot and spicy food.
2. Who have signed informed consent. Exclusion Criteria
1. Patients who have taken any medication for OLP within 4 weeks before the start of study.
2. Pregnant and lactating women.
3. History of lichenoid reactions to beta blockers, dapsone, oral hypoglycemics, NSAIDS,
pencillamine, phenothiazines, sulfonylureas, gold salts or amalgam fillings.
Sample Size All consecutive OLP patients will be evaluated according to
inclusion/exclusion criteria and at least 32 subjects will be enrolled they will be
randomly divided into study and control groups.
The sample size is calculated by the following formula keeping the power of study equal
to 90% and level of significance equal to 0.05. The sample size should be 16 in each
group.
[p1(1 - p1) + p2 (1 - p2)] n = × cp,power (p1 - p2)2 (Whitley and Ball, 2002) Desired
Level of Significance = 0.05 P1= proportion 1= 70% (0.7) P2= proportion 2= 30% (0.3) Cp,
power = 90% =10.5 Sample size in each group = 16 Randomization Randomization will be
done by allowing each patient to pick a sealed envelope from a box containing 40
envelopes of which 20 are of study and 20 are of control group.
Study Variables Socio-demographic/Medical parameters • Age (years), • Gender (male /
female), • Education (no-education / secondary / University), • Income (<10000.00- /
10-20000.00 / >20000.00),
• Smoking (never / former / current),
• Systemic conditions (CVD / DM / Hepatic / Rheumatoid Arthritis etc),
• Medications
• Oral hygiene habits (brushing, floss, dental visit)
Oral parameters
- Dimensions of lesion will be measured by with the help of a UNC-12 probe (HDL®
Pakistan).
- Color of lesion will be recorded by standardized pre and post treatment
photographic record.
- Pain or burning sensation will be evaluated by visual analogue scale (VAS).
- Clinical response (improvement of lesions and symptoms) will be assessed by
criteria given by (Escudier et al., 2007).
Data Collection Method and Instruments After approval from the ethical review committee,
patients will be included in the study. Written informed consent will be obtained from
all patients prior to the study as a part of ethical practice. 40 patients of
symptomatic OLP will be enrolled in the study after evaluation through punch biopsy and
other inclusion and exclusion criteria to compensate the loss to follow up as the actual
size calculated from the formula was 32. They will be randomly divided in to study and
control group each containing 20 patients. At baseline visit after recording the
socio-demographic and oral parameters data the local irritant factors in the oral cavity
which can aggravate the OLP will be removed by doing basic oral procedures like scaling
and root planning restorations, rounding of sharp cusps and replacement of any ill
fitting appliances in both the groups.
Study group will be given a cocktail containing dexamethasone, doxycycline, nystatin and
promethazine and will be advised to rinse with 1 and half teaspoon of this cocktail 3
times a day for 2 minutes for the period of 8 weeks and do not eat or drink anything 30
minutes after its use. Study group will also advised to apply triamcinolone orabase
containing 0.1% triamcinolone on lesions 3 times a day for the period of 8 weeks. The
control group will be advised to apply only triamcinolone orabase 3 times a day for 8
weeks with the same protocol. Assessment of dimension of lesions, color, pain and
burning sensation and improvement of lesions and symptoms will be done at baseline and
after 4 and 8 weeks.
Statistical Analysis The data will be coded and entered using SPSS ver 20. All the
numerical variables will be presented as mean and standard deviation while the
categorical variables will be reported as frequencies and percentages. the comparison of
efficacy between two groups will be done through chi-square test.
For all analysis a p-value of > 0.05 will be considered significant with a confidence
level of 95%
Ethical Considerations:
Patients fulfilling the inclusion criteria will be informed about the aim of study,
risks, benefits and a consent form will be signed by them. Study will be approved by
Institutional Review Board (IRB), The University of Faisalabad.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05997173 -
The Regulatory Role of Immune Response in Oral Lichen Planus
|
||
Completed |
NCT02443311 -
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT00484250 -
Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Not yet recruiting |
NCT06428630 -
Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus
|
Early Phase 1 | |
Completed |
NCT04193748 -
Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)
|
Phase 4 | |
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Recruiting |
NCT06135805 -
Impact of Fluocinonide 0,05% in Oral Lichen Planus
|
N/A | |
Completed |
NCT04289233 -
Molecular & Cellular Characterisation of Oral Lichen Planus
|
||
Completed |
NCT04293718 -
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
|
||
Completed |
NCT00525421 -
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
|
Phase 2 | |
Not yet recruiting |
NCT04091698 -
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
|
Phase 1 | |
Completed |
NCT03386643 -
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
|
Phase 2 | |
Withdrawn |
NCT03836885 -
Apremilast - Oral Lichen Planus Trial
|
Phase 2 | |
Completed |
NCT05730855 -
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
|
||
Completed |
NCT03257228 -
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)
|
N/A | |
Recruiting |
NCT03026478 -
Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
|
Phase 2 | |
Completed |
NCT02858297 -
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT02834520 -
Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus
|
N/A | |
Completed |
NCT02106468 -
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
|
Phase 2 |